<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522142</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 81776-101</org_study_id>
    <nct_id>NCT03522142</nct_id>
  </id_info>
  <brief_title>A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics,
      pharmacodynamics, and early clinical activity of single-agent INCB081776 (Part 1) and
      INCB081776 in combination with nivolumab (Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Identification of a pharmacologically active dose (PAD) and/or maximum tolerated dose (MTD) (whichever is lower) of INCB081776</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To establish a PAD and/or MTD of INCB081776 for further investigation in participants with advanced solid tumors who have failed prior treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Identification of the recommended Phase 2 dose (RP2D) of INCB081776</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>To establish an RP2D of INCB081776 for further investigation in participants with advanced solid tumors who have failed prior treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Identification of a PAD and/or MTD (whichever is lower) of INCB081776 in combination with nivolumab.</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To establish a PAD and/or MTD of INCB081776 in combination with nivolumab for further investigation in participants with advanced solid tumors who have failed prior treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Identification of the RP2D of INCB081776 in combination with nivolumab</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>To establish an RP2D of INCB081776 in combination with nivolumab for further investigation in participants with advanced solid tumors who have failed prior treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Number of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Screening through 100 days after end of treatment, up to approximately 1 year.</time_frame>
    <description>A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Cmax of INCB081776</measure>
    <time_frame>Up to approximately 3 weeks.</time_frame>
    <description>Maximum observed plasma or serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Tmax of INCB081776</measure>
    <time_frame>Up to approximately 3 weeks.</time_frame>
    <description>Time to maximum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: t½ of INCB081776, which will be summarized</measure>
    <time_frame>Up to approximately 3 weeks.</time_frame>
    <description>Apparent terminal-phase disposition half life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Pharmacokinetic/ pharmacodynamic correlation of AXL inhibition</measure>
    <time_frame>Up to approximately 3 weeks.</time_frame>
    <description>To evaluate the pharmacodynamics of INCB081176 as determined by target inhibition of AXL in participants with advanced solid tumors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Overall response rate</measure>
    <time_frame>Up to approximately 1 year.</time_frame>
    <description>Defined as the percentage of participants having complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Disease control rate</measure>
    <time_frame>Up to approximately 1 year.</time_frame>
    <description>Defined as the percentage of participants having CR, PR, or stable disease (SD) per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Duration of response</measure>
    <time_frame>Up to approximately 1 year.</time_frame>
    <description>Defined as the time from earliest date of disease response until the earliest date of disease progression (per RECIST v1.1) or death due to any cause, if occurring sooner than progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INCB081776</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-agent INCB081776.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB081776 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB081776 in combination with nivolumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB081776</intervention_name>
    <description>INCB081776 administered once daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.</description>
    <arm_group_label>INCB081776</arm_group_label>
    <arm_group_label>INCB081776 + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab administered intravenously according to the label as 240 mg every 2 weeks.</description>
    <arm_group_label>INCB081776 + Nivolumab</arm_group_label>
    <other_name>OPDIVO®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1
             that are considered nonamenable to surgery or other curative treatments or procedures.

          -  Must have received or been intolerant to standard therapy.

          -  Eastern Cooperative Oncology Group performance status score of 0 or 1.

          -  Willingness to avoid pregnancy or fathering children as per protocol-defined criteria.

        Exclusion Criteria:

          -  Laboratory values not within the protocol-defined range.

          -  History of retinal disease as defined in the protocol.

          -  Clinically significant cardiac disease as per protocol-defined criteria.

          -  History or presence of an ECG that, in the investigator's opinion, is clinically
             meaningful as per protocol-defined criteria.

          -  Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases
             that have progressed as per protocol-defined criteria.

          -  Active or inactive autoimmune disease or syndrome that has required systemic treatment
             in the past 2 years or receiving systemic therapy for an autoimmune or inflammatory
             disease.

          -  Prior Grade 3 or higher immune-related AEs or any ocular toxicity on prior
             immunotherapy as per protocol-defined criteria.

          -  Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or
             treatment with any anticancer medications or investigational drugs within the
             protocol-defined intervals.

          -  Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy and/or
             complications from prior surgical intervention before starting study treatment.

          -  Active infection requiring systemic therapy.

          -  Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

          -  Known history of HIV (HIV 1/2 antibodies).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Rubin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>AXL</keyword>
  <keyword>MER</keyword>
  <keyword>AXL/MER</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

